| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500056 | Farmacia Hospitalaria | 2012 | 7 Pages |
Abstract
treatment of MS patients with IFNβ is discontinued mainly due to lack of efficacy and adverse effects. Greater understanding of patients' views can help to identify those at greatest risk of lack of adherence, thereby helping to improve treatment.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
C. Vicente Iturbe, J.R. Ara Callizo, R. Huarte Lacunza, H. Navarro Aznárez, N. Serrano Mislata, M.J. Rabanaque Hernández,